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###### The paper explained

Problem {#emmm201910941-sec-0002}
=======

Therapy resistance is one of the main causes of death in breast cancer patients. During the course of treatment, acquisition of new genetic alterations can favour oncogene independence and therefore progression of the disease. Chromosome instability (CIN) acts as a powerful source of variability, compromising the efficacy of targeted therapy.

Results {#emmm201910941-sec-0003}
=======

Using a Kras‐driven breast cancer mouse model, we showed that genomically unstable tumours have high chances of persisting during treatment. Furthermore, initially stable tumours are also able to acquire CIN as a resistance mechanism.

Impact {#emmm201910941-sec-0004}
======

This study points out the important role of CIN in acquisition of therapy resistance and highlights the necessity to combine current treatments with drugs that specifically impair progression of unstable cells.

Introduction {#emmm201910941-sec-0005}
============

Chromosome instability (CIN) is a widespread phenomenon in malignancies characterized by the inability of a cell to maintain its diploid chromosome number, leading to a state of aneuploidy. Advances in DNA sequencing technologies have allowed for the high‐throughput visualization of tumour genomes and revealed the pervasiveness and diversity of aneuploidy across cancers (Cancer Genome Atlas Research Network *et al*, [2013](#emmm201910941-bib-0005){ref-type="ref"}; Zack *et al*, [2013](#emmm201910941-bib-0035){ref-type="ref"}).

Indeed, 90% of solid and 75% of hematopoietic tumours display aneuploidy (Duijf *et al*, [2013](#emmm201910941-bib-0009){ref-type="ref"}) and are thus thought to have gone through periods of CIN to obtain it. Though CIN is often reported to cause whole or partial chromosome changes, it is also known to cause smaller focal somatic copy number alterations (SCNAs) including amplifications and deletions (Janssen *et al*, [2011](#emmm201910941-bib-0013){ref-type="ref"}; Burrell *et al*, [2013](#emmm201910941-bib-0004){ref-type="ref"}).

Although many SCNAs are clearly pro‐tumorigenic (e.g. lower expression of TP53 via whole chromosome loss or focal amplification of KRAS), the majority are thought to be detrimental to the cell (Sansregret & Swanton, [2017](#emmm201910941-bib-0029){ref-type="ref"}). High levels of CIN and thus high rates of SCNA generation may lead to imbalanced expression of proteins encoded on the affected DNA regions, endangering the survival of a tumour\'s lineage. It is becoming clear that an optimal level of CIN can be achieved that is tolerated by tumour cells while promoting diversification of subclones and facilitating adaptation to selective pressures (e.g. drug treatment) during tumour development (Rowald *et al*, [2016](#emmm201910941-bib-0028){ref-type="ref"}).

Despite recent advances in detection and therapy, breast cancer remains the second leading cause of cancer‐related death in women and approximately 20% of breast cancer patients develop recurrent disease following treatment. Therefore, understanding the mechanism by which breast tumours recur and develop therapeutic resistance is critical. Several mechanisms have been observed to date such as activating point mutations in PIK3CA, loss of PTEN or overexpression of cMET (Nagata *et al*, [2004](#emmm201910941-bib-0024){ref-type="ref"}; Berns *et al*, [2007](#emmm201910941-bib-0001){ref-type="ref"}; Shattuck *et al*, [2008](#emmm201910941-bib-0030){ref-type="ref"}).

Mouse models of human cancer provide a suitable setting to look at the molecular and temporal dynamics of tumour recurrence via evolution of oncogene independent subclones. In a recent study, using a mouse model of Braf‐induced melanoma, Kwong *et al* ([2017](#emmm201910941-bib-0016){ref-type="ref"}) show that under strong selective pressure, genetically stable tumours acquire treatment resistance by mutating and thereby reactivating the initiating oncogenic pathway whereas genomically unstable tumours acquire broad whole chromosome aneuploidies which presumably afford their oncogene independence via a yet unidentified mechanism. Whether this is a general phenomenon for all cancer types or whether it only applies to this model is not known.

Mad2 is a central component of the spindle assembly checkpoint responsible for ensuring proper separation of sister chromatids. Its overexpression is commonly found in human cancers and leads to the hyperstabilization of kinetochore‐microtubule attachments that can result in mitotic arrest and improper correction of erroneous attachments causing lagging chromosomes, misalignments and consequently, aneuploidy (Rowald *et al*, [2016](#emmm201910941-bib-0028){ref-type="ref"}). Moreover, this ongoing CIN induced by Mad2 overexpression can circumvent oncogene addiction, compromising the effectiveness of targeted therapies thereby facilitating tumour relapse and persistence in lung and breast cancer models (Sotillo *et al*, [2010](#emmm201910941-bib-0032){ref-type="ref"}; Rowald *et al*, [2016](#emmm201910941-bib-0028){ref-type="ref"}). Using a doxycycline‐inducible mouse model of mutant Kras, we showed that mice develop multiple invasive mammary adenocarcinomas within 147 days, while the additional overexpression of Mad2 delays tumour onset (221 days) and increases the levels of CIN in the resultant breast tumours (Rowald *et al*, [2016](#emmm201910941-bib-0028){ref-type="ref"}). Moreover, downregulation of Kras or Kras and Mad2 in these fully formed breast tumours leads in some cases to the development of resistance (Rowald *et al*, [2016](#emmm201910941-bib-0028){ref-type="ref"}).

These results suggest that withdrawal of the oncogenic driver event in the presence of ongoing CIN would not be deleterious as this would enable further gain or loss of chromosomal regions that could sustain tumour growth. Here, we show that both low CIN and high CIN breast cancer models may resist oncogene withdrawal by activating effectors in downstream or parallel pathways to the initiating oncogene and further characterize the temporal effects of CIN on disease progression. Furthermore, we demonstrate that the few initially low CIN tumours that manage to resist oncogene withdrawal do so by acquiring CIN and achieving similar SCNA levels as initially high CIN tumours when faced with the pressure of oncogene withdrawal.

Results {#emmm201910941-sec-0006}
=======

Oncogene independent Kras and Kras/Mad2 tumours show high levels of chromosomal instability {#emmm201910941-sec-0007}
-------------------------------------------------------------------------------------------

Doxycycline‐inducible mouse models of Kras^G12D^ (K) and Kras^G12D^/Mad2 (KM) allow us to mimic targeted therapy since doxycycline withdrawal leads to complete silencing of the transgenes. Downregulation of Kras expression or Kras and Mad2 in fully formed mammary tumours results in their regression to a nonpalpable state in the vast majority of the cases. However, 6.6% of K and 21.3% of KM tumours did not fully regressed and were able to continue growing (Rowald *et al*, [2016](#emmm201910941-bib-0028){ref-type="ref"}). This indicates that, despite the initial detrimental effect of Mad2 overexpression, these resulting highly unstable tumours have increased chances to develop therapy resistance. Moreover, supporting the idea that chromosomal instability at primary tumour level confers advantages in strong pressure environments such as during targeted therapy, KM tumours needed on average 46 days to grow back while K tumours needed 93 days.

To evaluate chromosome segregation fidelity in these tumours that did not regress upon doxycycline withdrawal or that partially regressed and resumed growth (termed non‐regressed), we performed time‐lapse microscopy of the non‐regressed mammary tumour‐derived cells. Interestingly, we found that, while KM primary tumours were significantly more unstable than K primary tumours (Rowald *et al*, [2016](#emmm201910941-bib-0028){ref-type="ref"}), K and KM non‐regressed tumours showed similar percentages of mitotic errors, surpassing in both cases the already high level of CIN found in KM primary tumours (Fig [1](#emmm201910941-fig-0001){ref-type="fig"}A and B). Regardless of the genotype, we observed lagging chromosomes, chromosome bridges and misaligned chromosomes to be the major mitotic errors in the non‐regressed tumours (Fig [1](#emmm201910941-fig-0001){ref-type="fig"}C). Interestingly, there was an increase in the percentage of chromosome bridges in the non‐regressed tumours compared to the primary tumours, suggesting that non‐regressed tumours acquire different mitotic errors. These results suggest that genomically stable tumours (K) are able to acquire a certain level of CIN during the course of acquiring therapeutic resistance, although initially unstable tumours (KM) have an increased chance of persisting during treatment.

![Non‐regressed K and KM tumours show high levels of chromosomal instability\
ARepresentative micrographs of a time‐lapse microscopy of K and KM non‐regressed tumour cells (H2B‐GFP green). Top: mitotic cell with a chromatin bridge (yellow arrow). Bottom: mitotic cell with misalignment and cytokinesis failure resulting in binucleation (yellow arrow).BPercentage of mitotic errors in K and KM primary tumours and in K and KM non‐regressed tumours. Ns: not significant; \**P* \< 0.01, \*\*\*\**P* \< 0.0001; one‐way ANOVA, Turkey\'s multiple comparison test. Mean ± SEM. Exact *P* values are indicated in [Appendix Table S1](#emmm201910941-sup-0001){ref-type="supplementary-material"}.CPercentage of cells in K and KM primary tumours and in K and KM non‐regressed tumours with the indicated mitotic errors. Scale bar 20 μm.Data information: K primary (*n *= 4; 74 cells), KM primary (*n* = 5; 84 cells), K non‐Regr (*n* = 7; 219 cells), KM non‐Regr (*n* = 5; 247 cells).Source data are available online for this figure.](EMMM-12-e10941-g002){#emmm201910941-fig-0001}

Sequencing of oncogene independent Kras and Kras/Mad2 tumours reveals recurrent SCNAs {#emmm201910941-sec-0008}
-------------------------------------------------------------------------------------

To determine which alterations were involved in promoting oncogene independence, 7 K and 16 KM non‐regressed tumours were subjected to low‐pass whole‐genome sequencing using an Illumina HiSeq platform, followed by somatic copy number alteration (SCNA) analysis (Fig [2](#emmm201910941-fig-0002){ref-type="fig"}A). Similar to what we found in primary tumours, genomes of KM non‐regressed tumours were more frequently affected than K tumours. However, in line with the live imaging results, the mean of SCNAs was not significantly increased compared to K non‐regressed tumours (Figs [2](#emmm201910941-fig-0002){ref-type="fig"}A and [EV1](#emmm201910941-fig-0001ev){ref-type="fig"}A). Notably, some recurrent alterations in these tumours were a whole gain of chromosome 15 in 1.2% of K and 6.5% of KM non‐regressed tumours (Fig [EV1](#emmm201910941-fig-0001ev){ref-type="fig"}B and C) and a deletion, a partial chromosome loss and in 2 KM non‐regressed tumours a gross rearrangement of chromosome 4. However, we found that the most frequent alteration in either cohort was a small \~2 megabase amplification on chromosome 6, present in 57% of K and 62.5% of KM non‐regressed tumours. While whole gain of chromosome 15 and deletions and partial deletions of chromosome 4 were already present in some K and KM primary tumours (Fig [EV1](#emmm201910941-fig-0001ev){ref-type="fig"}D and Rowald *et al*, [2016](#emmm201910941-bib-0028){ref-type="ref"}), amplifications in chromosome 6 were detected for the first time in the non‐regressed tumours.

![Recurrent somatic copy number alterations in K and KM non‐regressed tumours\
ASomatic copy number alterations in each individual Kras and Kras/Mad2 non‐regressed tumours. 7 K non‐regressed and 16 KM non‐regressed tumours were sequenced. Focal deletion (DEL, green), focal amplification (AMP, light green), whole chromosome gain (WCG, dark grey) and loss (WCL, light grey), partial chromosome gain (PCG, dark blue) and loss (PCL, light blue) and gross chromosomal rearrangement (GCR, red).BOverlaying of the amplifications in chromosome 6 across multiple regions showing that all amplicons contained the cMet oncogene. Colour of the block corresponds to the segment mean (the degree to which a genome segment is lost (blue) or gained (red).CImmunostaining of phospho‐cMet in non‐regressed tumours carrying or not the amplification in chromosome 6. Yellow numbers indicate the total number of cMet‐positive cells/total number of cells counted. Scale bar 100 μm. Numbers of the K and KM non‐regressed tumours are described in Table [1](#emmm201910941-tbl-0001){ref-type="table"}.\
Source data are available online for this figure.](EMMM-12-e10941-g004){#emmm201910941-fig-0002}

![Related to Fig [2](#emmm201910941-fig-0002){ref-type="fig"}. Somatic copy number alterations in K and KM primary and non‐regressed tumours\
AAverage of somatic copy number alteration (SCNAs) in K and KM non‐regressed tumours. Unpaired *t*‐test, *P* = 0.34. Boxes and whiskers represent min to max values. The central line represents the median.BPercentage of SCNAs per chromosome in K (green) and KM (blue) non‐regressed tumours.CHeatmap of all chromosomes in the non‐regressed tumours.DFrequency of somatic copy number alterations per chromosome in Kras and Kras/Mad2 primary tumours. Focal amplification (AMP, dark green), whole chromosome gain (WCG, dark grey) and loss (WCL, light grey), partial chromosome gain (PCG, dark blue) and loss (PCL, light blue) and gross chromosomal rearrangement (GCR, red).\
Source data are available online for this figure.](EMMM-12-e10941-g003){#emmm201910941-fig-0001ev}

In an attempt to investigate the mechanism driving resistance, we focused on those tumours that did not re‐express oncogenic Kras, as reactivation of the oncogenic driver was most probably driving resistance. Moreover, we reasoned that, if the chromosomal alterations were already present in the primary tumour, they might represent genomic events that cooperated with the oncogenic driver in facilitating mammary tumour formation but not involved in resistance. Finally, since amplification of chromosome 6 was the most frequently detected alteration, we focused on those tumours that presented this amplification. Read depth analysis revealed variation in both the size and copy number pattern of the amplicons, with some presenting concise duplications and others showing complex copy number alterations resembling more elaborate mechanisms such as breakage‐fusion‐bridge cycles (Gisselsson *et al*, [2000](#emmm201910941-bib-0012){ref-type="ref"}; Fig [EV2](#emmm201910941-fig-0002ev){ref-type="fig"}A). However, overlaying the amplifications across multiple regions revealed that all amplicons contained the Met oncogene (Fig [2](#emmm201910941-fig-0002){ref-type="fig"}B).

![Related to Fig [2](#emmm201910941-fig-0002){ref-type="fig"}. cMet analysis in non‐regressed tumours\
AGenome‐wide log~2~ of chromosome 6 of control mammary gland and log~2~‐ratio plots of K and KM non‐regressed tumour biopsies showing no amplification in the control (upper panels) and a small amplification in the non‐regressed tumours (middle and bottom panels).BQuantitative RT--PCR analysis of cMet in 10 K and 22 KM non‐regressed tumours.CCorrelation analysis of cMet mRNA and gene amplification in K (green) and KM (blue) non‐regressed breast tumours.\
Source data are available online for this figure.](EMMM-12-e10941-g005){#emmm201910941-fig-0002ev}

Met gene encodes for the receptor tyrosine kinase cMET, mainly expressed in cells of mesenchymal origin and implicated in the activation of proliferation, survival, motility and morphogenesis signalling pathways (Birchmeier *et al*, [2003](#emmm201910941-bib-0002){ref-type="ref"}). Deregulation of cMET by gene amplification, overexpression or activating mutations (Tokunou *et al*, [2001](#emmm201910941-bib-0033){ref-type="ref"}; Lengyel *et al*, [2005](#emmm201910941-bib-0019){ref-type="ref"}) has been found in a variety of carcinomas, although the most common alteration is gene amplification and consequently protein overexpression and activation (Di Renzo *et al*, [1995](#emmm201910941-bib-0008){ref-type="ref"}). Analysis of cMet mRNA in K and KM non‐regressed breast tumours (Fig [EV2](#emmm201910941-fig-0002ev){ref-type="fig"}B) revealed a direct correlation between gene amplification and mRNA levels (Fig [EV2](#emmm201910941-fig-0002ev){ref-type="fig"}C). Moreover, immunohistochemistry against phospho‐cMet was positive in those tumours containing the chromosome 6 amplification and negative in the ones where the amplification was not present (Fig [2](#emmm201910941-fig-0002){ref-type="fig"}C and Table [1](#emmm201910941-tbl-0001){ref-type="table"}).

###### 

Non‐regressed tumours used in this study

  Genotype          Name   Sequenced \# SCNA   cMet ampl. by seq.   cMet upreg. QPCR Fig [EV2](#emmm201910941-fig-0002ev){ref-type="fig"}B   cMet upreg. IHC Fig [2](#emmm201910941-fig-0002){ref-type="fig"}C   Kras re‐expression[a](#emmm201910941-note-0002){ref-type="fn"}
  ----------------- ------ ------------------- -------------------- ------------------------------------------------------------------------ ------------------------------------------------------------------- ----------------------------------------------------------------
  Kras^G12D^        K1     1                   YES                  YES                                                                      61%                                                                 NO
  Kras^G12D^        K3     2                   YES                  YES                                                                      36%                                                                 NO
  Kras^G12D^        K4     3                   YES                  YES                                                                      28%                                                                 NO
  Kras^G12D^        K5     4                   YES                  YES                                                                      9%                                                                  NO
  Kras^G12D^        K6     n.d.                n.d.                 YES                                                                      n.d.                                                                NO
  Kras^G12D^        K2     3                   NO                   NO                                                                       0%                                                                  NO
  Kras^G12D^        K7     0                   NO                   NO                                                                       0%                                                                  YES
  Kras^G12D^        K8     n.d.                NO                   NO                                                                       n.d.                                                                NO
  Kras^G12D^        K9     n.d.                NO                   NO                                                                       n.d.                                                                YES
  Kras^G12D^        K10    1                   NO                   NO                                                                       n.d.                                                                NO
  Kras^G12D^        K11    n.d.                n.d.                 n.d.                                                                     n.d.                                                                n.d.
  Kras^G12D^/Mad2   KM2    3                   YES                  YES                                                                      39%                                                                 NO
  Kras^G12D^/Mad2   KM3    4                   YES                  YES                                                                      18%                                                                 NO
  Kras^G12D^/Mad2   KM4    n.d.                n.d.                 YES                                                                      n.d.                                                                NO
  Kras^G12D^/Mad2   KM5    4                   YES                  YES                                                                      39%                                                                 NO
  Kras^G12D^/Mad2   KM7    2                   YES                  YES                                                                      28%                                                                 YES. Low
  Kras^G12D^/Mad2   KM8    3                   YES                  YES                                                                      44%                                                                 yes
  Kras^G12D^/Mad2   KM11   2                   YES                  YES                                                                      12%                                                                 NO
  Kras^G12D^/Mad2   KM12   6                   YES                  YES                                                                      13%                                                                 NO
  Kras^G12D^/Mad2   KM15   1                   YES                  YES                                                                      42%                                                                 NO
  Kras^G12D^/Mad2   KM20   5                   YES                  YES                                                                      11%                                                                 NO
  Kras^G12D^/Mad2   KM21   1                   YES                  YES                                                                      11%                                                                 NO
  Kras^G12D^/Mad2   KM22   4                   YES                  YES                                                                      35%                                                                 YES
  Kras^G12D^/Mad2   KM1    n.d.                n.d.                 NO                                                                       0%                                                                  NO
  Kras^G12D^/Mad2   KM6    2                   NO                   NO                                                                       0%                                                                  NO
  Kras^G12D^/Mad2   KM9    n.d.                n.d.                 NO                                                                       n.d.                                                                Yes
  Kras^G12D^/Mad2   KM10   3                   NO                   NO                                                                       0%                                                                  NO
  Kras^G12D^/Mad2   KM13   n.d.                n.d.                 NO                                                                       n.d.                                                                NO
  Kras^G12D^/Mad2   KM14   1                   NO                   NO                                                                       n.d.                                                                NO
  Kras^G12D^/Mad2   KM16   2                   NO                   NO                                                                       n.d.                                                                NO
  Kras^G12D^/Mad2   KM17   n.d.                n.d.                 NO                                                                       n.d.                                                                YES
  Kras^G12D^/Mad2   KM18   n.d.                n.d.                 NO                                                                       n.d.                                                                YES
  Kras^G12D^/Mad2   KM19   0                   NO                   NO                                                                       n.d.                                                                YES Low
  Kras^G12D^/Mad2   KM23   n.d.                n.d.                 n.d.                                                                     n.d.                                                                n.d.

n.d: not done.

Rowald *et al* ([2016](#emmm201910941-bib-0028){ref-type="ref"}).

John Wiley & Sons, Ltd

cMet amplification is not clonally dominant in primary tumours {#emmm201910941-sec-0009}
--------------------------------------------------------------

To clarify whether the amplification on chromosome 6 was already present in the primary tumour, we first looked at the tumour evolution after doxycycline withdrawal and noticed that following a first period where tumours underwent a reduction in size, they continued to grow (Fig [3](#emmm201910941-fig-0003){ref-type="fig"}A). This suggests that in case cMet amplification was not present in the primary tumour, it could have been acquired during this timeframe, forced by the selective pressure that oncogenic silence exerted within the tumour. We then looked if cMet‐positive KM tumours resumed growth faster than K tumours. In fact, KM tumours partially regressed after doxycycline withdrawal and they needed an average of 38 days to grow back while K tumours took 133 days (Fig [3](#emmm201910941-fig-0003){ref-type="fig"}A), suggesting that already CIN tumours were more predispose to acquire this genetic modification.

![cMet amplification is not found in primary tumours\
ATumour diameter before and after doxycycline withdrawal in 4 K and 5 KM breast tumours with cMet amplification. 0 indicates when doxycycline was removed. Each colour represents one tumour. Blue and green squares indicate the timeframe between doxycycline withdrawal and the moment in which tumours resumed growth.BGenome‐wide log~2~‐ratio plots of chromosome 6 of two primary tumour biopsies and their corresponding non‐regressed tumour showing no amplification in the primary tumour (upper panels) and a small amplification in the non‐regressed tumours (bottom panels, yellow arrow).CImmunostaining of phospho‐cMet in 3 biopsied primary tumours (PT) and their corresponding non‐regressed tumours (KM5, KM7 and KM8, which are also shown in Fig [2](#emmm201910941-fig-0002){ref-type="fig"}C). Scale bar 100 μm.DRepresentative two‐dimensional scatter plots constructed with overlaid dPCR data of the reference (VIC) and cMet (FAM) from one tumour without cMet amplification and one with cMet amplified. Dots represent results of independent PCRs in the wells of a digital PCR chip. Reactions in the bottom left corner (yellow) are negative for both targets, while the ones in the top right corner (green) are double positives. Reactions in the top left (blue) and bottom right (red) corners are positive for cMet and the reference targets, respectively.ERepresentative photographs of FISH staining with a probe for Met (red signal) and a probe for a reference gene EML4 (green signals) The upper panel is a negative example for cMet amplification containing 2 red and 2 green dots (white arrows). The lower panel shows an example of a tumour with cMet amplification (several red dots) and 2 green dots (yellow arrow). Scale bar 10 μm.\
Source data are available online for this figure.](EMMM-12-e10941-g006){#emmm201910941-fig-0003}

Then, we determined the presence or absence of the cMet amplification in the primary tumours. We compared the low‐coverage sequenced genomes of two primary tumours that were biopsied and their corresponding non‐regressed tumours, after withdrawal of the oncogenic driver. As shown in Fig [3](#emmm201910941-fig-0003){ref-type="fig"}B, we found no detectable alterations in that specific region in the primary tumours. Additional immunohistochemistry staining of 3 biopsied primary tumours whose corresponding non‐regressed tumour contained a cMet amplification showed negative phospho‐cMet staining in the primary tumour and positive in the non‐regressed (Fig [3](#emmm201910941-fig-0003){ref-type="fig"}C). Additionally, we analysed a panel of primary tumours at the time point just before doxycycline withdrawal. Phospho‐cMet staining in 34 primary tumours was negative in all the tumour cells analysed (more than 400,000 cells in total; Fig [EV3](#emmm201910941-fig-0003ev){ref-type="fig"}).

![Related to Fig [3](#emmm201910941-fig-0003){ref-type="fig"}. cMet staining in primary tumours\
Immunostaining of phospho‐cMet in one non‐regressed tumour (KM15) as a positive control (as shown in Fig [2](#emmm201910941-fig-0002){ref-type="fig"}C) and 34 primary tumours (PT). Yellow numbers indicate the total number of cMet‐positive cells/total number of cells counted. Scale bar 100 μm.Source data are available online for this figure.](EMMM-12-e10941-g007){#emmm201910941-fig-0003ev}

To further examine whether cMet amplification could be present in a small population of the tumours undetectable by whole‐genome sequencing or immunohistochemistry, we resorted to analyse by digital PCR a panel of primary tumours at human endpoint (Fig [3](#emmm201910941-fig-0003){ref-type="fig"}D and Table [2](#emmm201910941-tbl-0002){ref-type="table"}). The measured ratio between cMet and a reference gene was never significantly different from 1 except for one primary tumour whose ratio was 1.5, a result explained by a whole chromosome 6 gain detected by whole‐genome sequencing (PT KM15) (Table [2](#emmm201910941-tbl-0002){ref-type="table"}). Finally, we looked at the single‐cell level for amplification of cMet by performing fluorescent *in situ* hybridization (FISH) with a probe against cMet. A probe recognizing EML4 gene was used as reference, given this gene is located in chromosome 17, which was almost never affected in the primary tumours. During the analysis, cells where 3 or more copies of cMet were accompanied by 3 or more copies of EML4 were discarded, since they might represent cells that underwent genome doubling. We found that the cMet:EML4 ratio on population level was close to 1 in all tumours, but on average 6.22% of cells in K and 5.67% of cells in KM tumours carried 3--5 copies of cMet (Fig [3](#emmm201910941-fig-0003){ref-type="fig"}E and Table [2](#emmm201910941-tbl-0002){ref-type="table"}). Although detection of cMet gene amplification by FISH has been previously considered positive when the number of copies exceed 5 in more than 15% of the nuclei (Cappuzzo *et al*, [2009](#emmm201910941-bib-0006){ref-type="ref"}), the FISH results were not sufficient to rule out the existence of cMet‐positive cells. Therefore, we sought to test whether these primary tumour cells carrying more than three copies of cMet were indeed dependent on cMet by evaluating the effect of a cMet inhibitor on tumour growth. We first recapitulated the primary tumours by injecting tumour cells from K and KM tumours into the cleared fat pad of Rag2^−/−^ immunocompromised animals (Fig [4](#emmm201910941-fig-0004){ref-type="fig"}A). When tumours reached 0.5 cm^3^, we treated them with the cMet inhibitor Tepotinib which has been proven to selectively inhibit the kinase activity of this protein, independently of its mechanism of activation (Bladt *et al*, [2013](#emmm201910941-bib-0003){ref-type="ref"}). We found no differences in tumour growth between control and treated mice (Fig [4](#emmm201910941-fig-0004){ref-type="fig"}B) and the results of FISH analysis of the treated tumours were similar to the untreated ones (Fig [4](#emmm201910941-fig-0004){ref-type="fig"}C). Moreover, the ratio treated/control obtained by dPCR was not significantly different from 1 in all tumours independently of the genotype (K or KM), suggesting that the presence of more than 2 copies of cMet in some of the cells did not lead to detectable difference in the sensitivity to the drug treatment in the tumour cell population.

###### 

Primary tumours used in this study

  Genotype          Name                                                  FISH MET: EML4   dPCR Ratio   \% p‐cMET^+^   
  ----------------- ----------------------------------------------------- ---------------- ------------ -------------- ---------
  Kras^G12D^        PT K1                                                 1.01             4.80         1.01           0/11313
  Kras^G12D^        PT K2                                                 1.02             4.55         1.02           0/7555
  Kras^G12D^        PT K3                                                 0.97             2.20         0.98           0/5307
  Kras^G12D^        PT K4                                                 1.01             5.05         0.99           0/10199
  Kras^G12D^        PT K5                                                                               0.98           0/22759
  Kras^G12D^        PT K6                                                 0.96             0.02         1.00           0/12067
  Kras^G12D^        PT K7                                                                               1.07           0/17125
  Kras^G12D^        PT K8                                                 0.97             6.41         0.95           0/16602
  Kras^G12D^        PT K9                                                                               1.06           0/11755
  Kras^G12D^        PT K10                                                                              1.01           0/16521
  Kras^G12D^        PT K11                                                1.01             4.12         1.05           0/7591
  Kras^G12D^        PT K12                                                                              1.03           0/14508
  Kras^G12D^        PT K13                                                0.95             5.77         0.87           0/13809
  Kras^G12D^        PT K14                                                1.02             14.50        0.93           0/9927
  Kras^G12D^        PT K15[a](#emmm201910941-note-0003){ref-type="fn"}                                  1.41           0/11764
  Kras^G12D^        PT K16                                                                              0.97           0/12892
  Kras^G12D^        PT K17                                                                                             0/10418
  Kras^G12D^        PT K18                                                                                             0/9657
  Kras^G12D^        PT K19                                                                                             0/13295
  Kras^G12D^        PT K20                                                                                             0/8469
  Kras^G12D^        PT K21                                                                                             0/8059
  Kras^G12D^        PT K22                                                                                             0/12054
  Kras^G12D^        PT K23                                                                                             0/9037
  Kras^G12D^        PT K24                                                1.43             21.00        0.99           0/12872
  Kras^G12D^        PT K25                                                0.97             3.30         0.83           0/11299
  Kras^G12D^        PT K26                                                1.01             3.00         1.02           
  Kras^G12D^        PT K27                                                                              1.06           
  Kras^G12D^        PT K28                                                                              1.01           
  Kras^G12D^        PT K29                                                                              0.98           
  Kras^G12D^        PT K30                                                                              0.96           
  Kras^G12D^        PT K31                                                                              0.96           
  Kras^G12D^        PT K32                                                                              0.97           
  Kras^G12D^        PT K33                                                                              1.00           
  Kras^G12D^/Mad2   PT KM1                                                1.008            3.51         0.92           0/6615
  Kras^G12D^/Mad2   PT KM2                                                1.004            1.83         0.89           0/14488
  Kras^G12D^/Mad2   PT KM3                                                                              0.98           0/14986
  Kras^G12D^/Mad2   PT KM4[a](#emmm201910941-note-0003){ref-type="fn"}                                  1.35           0/16605
  Kras^G12D^/Mad2   PT KM5                                                0.99             5.66         1.04           0/5409
  Kras^G12D^/Mad2   PT KM6                                                                                             0/8293
  Kras^G12D^/Mad2   PT KM7                                                                              1.00           0/4819
  Kras^G12D^/Mad2   PT KM8                                                1.009            2.98                        0/6987
  Kras^G12D^/Mad2   PT KM9                                                                                             0/12622
  Kras^G12D^/Mad2   PT KM10                                                                                            0/10461
  Kras^G12D^/Mad2   PT KM11                                               0.96             6.9                         0/13470
  Kras^G12D^/Mad2   PT KM12                                               1.02             13.15        1.02           0/6478
  Kras^G12D^/Mad2   PT KM13                                                                             1.00           
  Kras^G12D^/Mad2   PT KM14                                                                             0.48           
  Kras^G12D^/Mad2   PT KM15[b](#emmm201910941-note-0004){ref-type="fn"}   2.47             40.5         1.50           
  Kras^G12D^/Mad2   PT KM16                                                                             0.93           
  Kras^G12D^/Mad2   PT KM17                                                                             1.07           
  Kras^G12D^/Mad2   PT KM18                                                                             0.85           
  Kras^G12D^/Mad2   PT KM19                                                                             1.38           
  Kras^G12D^/Mad2   PT KM20                                                                             0.97           
  Kras^G12D^/Mad2   PT KM21                                                                             0.97           

Whole chromosome 16 loss (location of the reference gene used in the dPCR).

Whole chromosome 6 gain.

John Wiley & Sons, Ltd

![cMet amplification is not clonally dominant in primary tumours\
ASchematic of the experiment. K and KM animals were set on doxycycline food until mammary tumours developed. Primary tumours were collected and single cells injected into Rag2^−/−^ animals to recapitulate the tumours followed by either no treatment, drug treatment or switched to a normal diet.BRelative volume of tumours grown in 12 Rag2^−/−^ animals after treatment with Tepotinib or vehicle control (3K and 3KM tumours for each condition). No statistical significance was found by one‐way ANOVA. Mean ± SEM. Exact *P* values are indicated in [Appendix Table S2](#emmm201910941-sup-0001){ref-type="supplementary-material"}.CQuantification of cMet copy number detected by digital PCR or FISH in primary tumours injected into Rag2^−/−^ and treated with vehicle control or Tepotinib.DQuantification of cMet copy number detected by digital PCR or FISH in primary tumours injected into Rag2^−/−^ and fed with doxycycline or after doxycycline withdrawal.\
Source data are available online for this figure.](EMMM-12-e10941-g008){#emmm201910941-fig-0004}

Furthermore, we evaluated the presence of cMet amplification during regression, a few days after doxycycline withdrawal, since we considered it to be the most critical time point to claim an increase cMet activation after oncogene withdrawal. When primary tumours grown in Rag2^−/−^ mice reached 1 cm^3^, we removed doxycycline from the diet and monitored the tumours until they regressed to 0.5 cm^3^, giving them enough time for the possible acquisition of cMet amplification. FISH in these tumours (Fig [4](#emmm201910941-fig-0004){ref-type="fig"}D) showed a slight increase in the percentage of cells with more than 2 copies of cMet in few (1 K and 2 KM) tumours although the percentage of cells with more than five copies was close to 0%. Here again, dPCR measurement showed an equal ratio of cMet/reference in all tumours, suggesting that a significant cMet amplification did not occur during tumour regression.

Altogether, these results support the idea that *de novo* acquired chromosome alterations (such as the amplification of chromosome 6) could be responsible for driving the development of resistant subclones.

Resistant tumours are dependent on cMet {#emmm201910941-sec-0010}
---------------------------------------

To determine whether non‐regressed tumours depended on cMet expression to grow after withdrawal of the Kras initiating oncogene, we sought to determine whether they were sensitive to pharmacological cMet inhibition. We first recapitulated the non‐regressed tumours by injecting non‐regressed tumour cells from K and KM tumours into the cleared fat pad of Rag2^−/−^ immunocompromised animals (Fig [5](#emmm201910941-fig-0005){ref-type="fig"}A), and once tumours reached an average of 0.5 cm^3^, we treated the animals with the cMet inhibitor Tepotinib. After 5‐day treatment, Tepotinib strongly reduced tumour growth in cMet‐positive xenografts compared to a vehicle control, whereas no significant differences in growth were observed in tumours without cMet amplification between drug and vehicle group (Fig [5](#emmm201910941-fig-0005){ref-type="fig"}B). To further confirm the therapeutic ability of Tepotinib, the cMet‐positive xenografts were treated for 2 additional weeks. As shown in Fig [5](#emmm201910941-fig-0005){ref-type="fig"}B, after a first period in which tumours were sensitive to the drug, they resumed growth, suggesting that they became resistant to cMet inhibition.

![cMet amplified non‐regressed tumours respond to cMet treatment\
ASchematic of the experiment. K and KM animals were set on doxycycline food until mammary tumours developed. Then, switched to a normal diet and non‐regressed tumours collected. Single cells were then injected into Rag2^−/−^ animals to recapitulate the non‐regressed tumours followed by drug treatment or vehicle control treatment.BRelative volume of tumours grown in Rag2^−/−^ animals after treatment with Tepotinib or vehicle control. One‐way ANOVA, Tukey\'s multiple comparison. Ns: not significant; \*\**P* \< 0.024. Mean ± SEM. A total of 19 Rag2^−/−^ mice injected with cMet expressing tumours were treated with Tepotinib and 14 used as controls. For tumours with no cMet, 13 Rag2^−/−^ mice were treated with Tepotinib and 9 were used as control. Exact *P* values are indicated in [Appendix Table S3](#emmm201910941-sup-0001){ref-type="supplementary-material"}.CImmunostaining of phospho‐cMet in the same tumours grown in Rag2^−/−^ mice after treatment with Tepotinib or vehicle control. Scale bar 200 μm.DQuantification of pH3 in tumours grown in Rag2^−/−^ animals after 5 days treatment with the cMet inhibitor Tepotinib or vehicle control.EQuantification of caspase 3 in tumours grown in Rag2^−/−^ animals after 5 days treatment with the cMet inhibitor Tepotinib or vehicle control.Data information: (D, E) One‐way ANOVA, Tukey\'s multiple comparison; \*\**P* \< 0.005; \*\*\*\**P* \< 0.0001. Mean ± SEM. At least four tumours per condition were analysed, and a minimum of 35 fields of view (FOV) or 12,000 cells were counted for each condition. Exact *P* values are indicated in [Appendix Tables S3 and S4](#emmm201910941-sup-0001){ref-type="supplementary-material"}, respectively.Source data are available online for this figure.](EMMM-12-e10941-g010){#emmm201910941-fig-0005}

To confirm that cMet phosphorylation was inhibited upon short exposure to Tepotinib, we analysed the phosphorylation status of cMet in these xenografts. Tumours carrying cMet amplification were highly positive for phospho‐cMet after vehicle control treatment, while 5‐day treatment with Tepotinib impaired the *in vivo* phosphorylation of cMet (Fig [5](#emmm201910941-fig-0005){ref-type="fig"}C). As expected, cMet remained unphosphorylated upon vehicle treatment in non‐amplified cMet tumours. Altogether, these results suggest that K and KM resistant tumours that amplified cMet are dependent on cMet for survival as treatment with a specific cMet inhibitor hampers tumour growth.

Tepotinib binds specifically to cMet protein and impairs its activation and function, leading to cell cycle arrest and apoptosis (Bladt *et al*, [2013](#emmm201910941-bib-0003){ref-type="ref"}). To confirm that tumour reduction in cMet\\‐positive xenografts was a consequence of these two mechanisms, we quantified tumour cell proliferation (pH3^+^) and cell death (cleaved caspase 3^+^) (Figs [5](#emmm201910941-fig-0005){ref-type="fig"}D--E and [EV4](#emmm201910941-fig-0004ev){ref-type="fig"}). Strikingly, cMet‐positive tumours showed higher percentage of proliferating cells compared to cMet‐negative tumours (26.75% versus 9.33%, *P* \< 0.001; Figs [5](#emmm201910941-fig-0005){ref-type="fig"}D and [EV4](#emmm201910941-fig-0004ev){ref-type="fig"}), while treatment with Tepotinib in cMet‐positive tumours led to a significant reduction in pH3, showing equivalent levels to the cMet‐negative tumours. Importantly, cMet inhibition did not impinge on cell proliferation of cMet‐negative tumours, highlighting the specific effect of this inhibitor. Similarly, we found increased cell death in the mammary tissue of cMet‐positive tumours compared to the rest of groups in the study (Figs [5](#emmm201910941-fig-0005){ref-type="fig"}E and [EV4](#emmm201910941-fig-0004ev){ref-type="fig"}).

![Related to Fig [5](#emmm201910941-fig-0005){ref-type="fig"}. Proliferation and apoptosis in non‐regressed tumours\
Immunostaining of pH3 and caspase 3 in tumours with and without cMet amplification after treatment with Tepotinib or vehicle control. Scale bar 200 μm.Source data are available online for this figure.](EMMM-12-e10941-g009){#emmm201910941-fig-0004ev}

Altogether, these results confirm that all K and KM non‐regressed tumours that presented an amplification on chromosome 6 are addicted to cMet, since treatment with Tepotinib led to tumour regression by decreasing proliferation and inducing apoptosis, confirming that cMet is essential for the proliferation and/or viability of tumour cells.

Discussion {#emmm201910941-sec-0011}
==========

Tumour resistance and recurrence remain to date one of main causes of breast cancer‐related deaths. Underlying resistance is the principal of intra‐tumour heterogeneity, which expedites the generation of more malignant cancer cells or clones resistant to therapeutic intervention (McGranahan & Swanton, [2017](#emmm201910941-bib-0023){ref-type="ref"}). Indeed, the DNA index, a proxy for karyotypic heterogeneity, correlates with important clinical features including tumour size, grade, lymph node metastasis and ER status (Dayal *et al*, [2013](#emmm201910941-bib-0007){ref-type="ref"}). Here, we present results that mechanistically demonstrate how, in the context of breast tumorigenesis and oncogene withdrawal, CIN allows tumour cell populations to evolve past their dependence on their initiating oncogene via the production of oncogenic SCNAs (e.g. Met amplification).

Increasing number of studies have reported clonal mutations as a mechanism to resist both targeted and chemotherapy in many cancer types (Redmond *et al*, [2015](#emmm201910941-bib-0027){ref-type="ref"}). Nevertheless, treatment resistance can occur in tumours showing high levels of SCNA and CIN. In colorectal cancer, for instance, karyotypic heterogeneity might be responsible for drug resistance compared to karyotypically stable tumours (Lee *et al*, [2011](#emmm201910941-bib-0017){ref-type="ref"}) and also associated with worse prognosis (Walther *et al*, [2008](#emmm201910941-bib-0034){ref-type="ref"}). Moreover, Kwong and colleagues found that in an environment with strong selective pressure such as therapy, unstable tumours develop resistance by selecting for recurrent aneuploidies (Kwong *et al*, [2017](#emmm201910941-bib-0016){ref-type="ref"}). Supporting this idea, we found that upon doxycycline withdrawal, higher percentage of chromosomically unstable KM tumours were able to resist and continue growing compared to K tumours, indicating that the presence of CIN during primary tumour development increases the chance to develop therapy resistance in a model of Kras‐driven breast cancer (Rowald *et al*, [2016](#emmm201910941-bib-0028){ref-type="ref"}). Surprisingly, sequencing data from resistant tumours showed that although the percentage of genomic alterations per chromosome was higher in KM non‐regressed tumours, the total number of SCNAs in K and KM was similar (Figs [2](#emmm201910941-fig-0002){ref-type="fig"} and [EV1](#emmm201910941-fig-0001ev){ref-type="fig"}). Moreover, genomes of both K and KM resistant non‐regressing tumours were highly unstable with tumour cells frequently generating mitotic errors (Fig [1](#emmm201910941-fig-0001){ref-type="fig"}), suggesting that acquisition of a CIN phenotype might be a prerequisite for the development of therapy resistance. We found no correlation between the number of SCNAs present in the resistant tumours and the frequency of mitotic errors seen by video microscopy, probably due to the fact that resistant tumour cells are highly CIN and constantly evolving. We observed an increase in binucleated cells in non‐regressed compared to primary tumours, and although it will be tempting to speculate that tetraploidy could partly account for the increase in resistance in KM tumours, also an increase in chromosome bridges, misalignment and lagging chromosomes was observed. Interestingly, we noticed an increased number of chromosome bridges in the non‐regressed tumours from both K and KM genotypes compared to the primary tumours and further genomic analyses inferred that the complex copy number alterations resembled a mechanism of breakage‐fusion‐bridge cycle. The fact that in primary tumours of either K or KM genotypes, chromosome bridges were very rarely observed indicates that the breakage‐fusion‐bridge cycle (Gisselsson *et al*, [2000](#emmm201910941-bib-0012){ref-type="ref"}) could have occurred after doxycycline withdrawal. Although it will be difficult to directly test whether chromosome 6 is the one present in those bridges, it is important to note that gain of chromosome 6 has already been observed in mouse models of Ras‐ or EGFR‐driven lung cancer (McFadden *et al*, [2016](#emmm201910941-bib-0022){ref-type="ref"}).

MET alterations (mutations, deletions and amplifications) have been found in various human cancers (cBioPortal). Pan‐cancer analysis (Zehir *et al*, [2017](#emmm201910941-bib-0036){ref-type="ref"}) reveals that primary tumours with MET amplification have higher overall survival rate (11.83 months) compared to metastatic tumours (9.88 months). However, MET amplification appears at a very low percentage in different breast cancer data sets both in primary (TCGA BRCA (0.4%), (Pereira *et al*, [2016](#emmm201910941-bib-0025){ref-type="ref"}) (1.5%), (Razavi *et al*, [2018](#emmm201910941-bib-0026){ref-type="ref"}) (0.1%)) and metastatic tumours (2.3%) (Lefebvre *et al*, [2016](#emmm201910941-bib-0018){ref-type="ref"}), MBC project 2018 (1.3%), (0.2%) (Zehir *et al*, [2017](#emmm201910941-bib-0036){ref-type="ref"}), (0.15%) (Razavi *et al*, [2018](#emmm201910941-bib-0026){ref-type="ref"}). Future studies addressing the relationship between aneuploidy and MET under different oncogenic drivers could underline the importance of MET inhibitors as prognostic markers in the treatment of this disease.

The exact timing of the cMet amplification appearance remains elusive. There are evidences that suggest cMET amplification can be acquired *de novo*, induced by the treatment (Engelman *et al*, [2008](#emmm201910941-bib-0010){ref-type="ref"}). In our model, cMet amplification drives resistance in half of the tumours and confers a proliferative advantage compared to other genomic alterations present in the rest of the non‐regressed tumours. However, this amplification was not detected in any of the primary tumours analysed by whole‐genome sequencing, consistent with a model of acquired therapy resistance, such as the one described for glioblastoma (Kim *et al*, [2015](#emmm201910941-bib-0014){ref-type="ref"}). The absence of the cMet amplicon by DNA sequencing in biopsies of tumours whose corresponding non‐regressed tumour showed cMet amplification suggests that either the cells were present in very small numbers or that the amplification occurred after oncogene withdrawal. The use of more sensitive techniques such as dPCR and FISH provided further evidences against the possibility that this alteration was already present in the primary tumour and remained undetected due to insufficient sequencing depth. The ratio cMet:reference gene was not significantly different from 1 in 39 and 18 primary tumours analysed by dPCR and FISH, respectively, strengthening the idea that cMet amplification was acquired as a mechanism to overcome the selective pressure exerted by oncogene withdrawal.

In a recent study in triple‐negative breast cancer (TNBC), the authors found that the majority of the mutations present in therapy resistant patients were already present during pre‐treatment stages, although with lower frequencies after treatment. In addition, resistant patients showed higher levels of aneuploidy pre‐treatment than patients that responded to chemotherapy (Kim *et al*, [2018](#emmm201910941-bib-0015){ref-type="ref"}). In our model, therapy resistance arises more frequently in aneuploid primary tumours, very much in line with these observations. This is supported by the fact that all K and KM non‐regressed tumours carrying cMet amplification resumed growing in the presence of Tepotinib. Moreover, some alterations present in primary tumours such as whole gain of chromosome 15 and gross rearrangement of chromosome 4 showed even higher frequencies after treatment, suggesting that more unstable genotypes were positively selected during the course of the treatment.

In summary, we have shown that chromosomal instability acts as a source of genetic variability that under strong selective pressure, such as during targeted therapy, confers tumour cells with an evolutionary advantage. We further demonstrate that the few initially chromosomally stable cancers that manage to persist during treatment do so concomitantly with the acquisition of CIN and this increases the chances of developing secondary resistances. Future experiments using CIN mouse models together with different oncogenic drivers will be useful to advance our understanding of resistant mechanisms to targeted therapies.

Materials and Methods {#emmm201910941-sec-0012}
=====================

Mouse models {#emmm201910941-sec-0013}
------------

All animals were in a FVB background and generated as described in Rowald *et al* ([2016](#emmm201910941-bib-0028){ref-type="ref"}). Mad2 transgenic mice were the traditional TetO‐Mad2 (Sotillo *et al*, [2007](#emmm201910941-bib-0031){ref-type="ref"}) and TetO‐Kras^G12D^ were described in Fisher *et al* ([2001](#emmm201910941-bib-0011){ref-type="ref"}). All mice were housed in specific pathogen‐free conditions, and breeding and experimentation were performed at the EMBL and DKFZ animal facilities, in accordance with institutional guidelines, and were approved by the Regierungspräsidium Karlsruhe, Germany, under permit number G231/15. For transgene induction, 8‐week‐old females were treated with doxycycline, administrated via impregnated food pellets (625 mg/kg; Harlan‐Teklad). When tumour size reached 1 cm^2^, doxycycline food was replaced by normal food. Tumour growth was monitored regularly, and animals were sacrificed when their size reached 1.5 cm^3^. Rag xenografts: 250,000 tumour cells per sample were injected into the cleared fat pad of 21‐day‐old Rag2^−/−^ animals under isoflurane inhalation (2.5% in 0.8 l/min, Esteve) and in accordance with local disinfection and sterilization guidelines. Once tumours reached a volume of 0.5 cm^2^, we treated the animals daily by intraperitoneal injection with either Tepotinib (EMD1214063) (30 mg/kg) or vehicle (Solutol) (Bladt *et al*, [2013](#emmm201910941-bib-0003){ref-type="ref"}). Tumour size \[length (L) and width (W)\] was measured every 2 days, and the tumour volume was calculated using the formula L × W^2^/2.

Tumour cell culture {#emmm201910941-sec-0014}
-------------------

Harvested tumours were digested with 150 U/ml Collagenase type 3 (Worthington, CLS3) and 20 mg/ml Liberase Blendzyme 2 (Roche, 11988425001) for 1 h, washed with PBS and dissociated with 0.25% Trypsin (Life Technologies, 25200056). Cells (not tested for mycoplasma) were cultured on 6‐well plates (Corning) in serum‐free mammary epithelial basal medium (MEBM) with supplements (Lonza, CC‐3150). To generate H2B‐GFP expressing mammary tumours, cells were infected with a lentivirus carrying H2B‐GFP. For time‐lapse imaging, cells were cultured on 8‐well chambered cover glass (Thermo Scientific, 155411) and imaging during 15 h was performed on a Zeiss Cell Observer with 2‐μm optical sectioning across 18‐μm stack, 12 frames/h. Zeiss Zen 2 software served for image analysis.

Immunodetection in tissue sections {#emmm201910941-sec-0015}
----------------------------------

Immunohistochemistry was performed using formalin‐fixed paraffin‐embedded sections. Following deparaffinization with xylene and rehydration with graded ethanol, antigen retrieval was performed using 0.09% (v/v) unmasking solution (Vector Labs) for 30 min in a steamer. Inactivation of endogenous peroxidases was carried out using 3% hydrogen peroxide (Sigma) for 10 min. Secondary antibody staining and biotin--streptavidin incubation were performed using species‐specific VECTASTAIN Elite ABC Kits (Vector Labs). DAB Peroxidase Substrate Kit (Vector Labs) was utilized for antibody detection. Primary antibodies used were anti‐pH3 Ser10 (1:200, Cell Signalling, 9701), cleaved caspase 3 (1:200, Cell Signalling, 9661) and Phospho‐Met (Tyr1234/1235) (1:300, Cell Signaling, 3077). Tumour sections were visualized under a TissueFAXS slide scanning platform (TissueGnostics, Vienna, Austria). For the pH3 and Casp3, the quantitation was performed using StrataQuest software (TissueGnostics) to determine the percentage of pH3^+^ or Casp3^+^ cells.

FISH {#emmm201910941-sec-0016}
----

Interphase FISH was performed on formalin‐fixed paraffin‐embedded 5‐μm sections. Following deparaffinization with xylene and rehydration with graded ethanol, antigen retrieval was performed using 0.09% (v/v) unmasking solution (Vector Labs) for 30 min in a steamer. Tissues were digested with 0.005% Pepsin at 37°C for 15 min, washed with 2× saline/sodium citrate for 3 min and dehydrated in an ethanol series (70%, 85%, 100%) for 3 min each. Hybridization was performed using Abbott Molecular Thermobrite system with the following programme: denaturation 76°C for 5 min, hybridization at 37°C for 20 h. Posthybridization, washes were performed with 0.4× saline/sodium citrate/0.1% Tween20 at RT for 2 min; 0.4× saline/sodium citrate/0.1% Tween20 at 74°C for 2 min; cooled in 2× saline/sodium citrate/0.1% Tween20 for 2 min; and 2× saline/sodium citrate for 3 min. Finally, slides were mounted with Prolong Diamond (Life Technologies, P36966).

Fluorescent *in situ* hybridization probes were prepared from purified BAC clones RP23 clone 416H6 (for cMet gene located within A2 of chromosome 6) and RP23 clone 193B15 (for EML4 gene located in chromosome 17; Maddalo *et al*, [2014](#emmm201910941-bib-0021){ref-type="ref"}) labelled with Red 650‐dUTP (Enzo) and SpectrumOrange‐dUTP (Vysis), respectively, by nick translation according to standard procedures. Signal for hybridization for each probe was checked in a minimum of 70 interphase cells in each tumour sample. FISH samples were imaged using Zeiss Cell Observer microscope in the DKFZ Light Microscopy Facility. Images were analysed using FIJI software.

RNA work {#emmm201910941-sec-0017}
--------

Snap‐frozen tissue was grinded with mortar and pestle on dry ice. For RNA extraction, 30 mg of tissue was used. All further steps were performed via the RNeasy Mini Kit (Qiagen) according to technical specifications. For cDNA synthesis, we followed the specifications of the QuantiTect Reverse Transcription Kit (Qiagen). Real‐time quantification was performed on a starting material of 8 ng cDNA with SYBR Green PCR Master Mix (2×) (Applied Biosystems) in a LightCycler II^®^ 480 (Roche). Primers used were cMet F: CATTTTTACGGACCCAACCA and cMet R: TGTCCGATACTCGTCACTGC and actin F: GCTTCTTTGCAGCTCCTTCGT and actin R: ACCAGCCGCAGCGATATCG.

DNA sequencing and analysis {#emmm201910941-sec-0018}
---------------------------

Genomic DNA was extracted from mouse tumour cells using the DNA Blood Mini Kit (QIAGEN). Library preparation and low‐coverage sequencing (3×) were pursued on an Illumina HiSeq 2500 platform (Illumina) using 50‐base pair single‐end reads as described previously (Rowald *et al*, [2016](#emmm201910941-bib-0028){ref-type="ref"}). Reads were aligned to the mm10 build of the mouse reference genome using Burrows‐Wheeler Aligner (BWA; version 0.7.10; Li & Durbin, [2009](#emmm201910941-bib-0020){ref-type="ref"}). Coverage files were calculated and log~2~‐normalized to mouse genomic DNA derived from normal mammary tissue. Circular binary segmentation (CBS; R package) was applied, and somatic copy number alterations were categorized as follows. Whole chromosome gains/losses were defined as chromosome‐wide shifts in the segmentation of a chromosome, whereas partial chromosome gains/losses entailed changes spanning at least one‐fifth of the chromosome. Focal amplifications and deletion encompassed events smaller than this. When the number of copy number state switches on a chromosome exceeded ten, we called them gross chromosomal rearrangements.

Digital PCR {#emmm201910941-sec-0019}
-----------

Genomic DNA was extracted from mouse tumour cells, and DNA samples were dispensed in the chip‐based QuantStudio^™^ 3D Digital PCR System (Thermo Fisher Scientific) and amplified using selected TaqMan^™^ CNV Assays for mouse cMET gene (Mm00193012_cn). Mouse TFRC or TERT was used as reference gene (4458367 and 4458368, Thermo Fisher Scientific). dPCRs were set up in a final volume of 14.5 μl, containing 7.5 μl of 2× QuantStudio^™^ 3D Digital PCR Master Mix, 0.725 μl of each TaqMan^®^ probe (Life Technologies) and 15 ng of gDNA templates adjusted in 5.8 μl water. Thermal cycling was as follows: 10 min at 96°C, 39 cycles at 60°C for 2 min, 30 s at 98°C and a final elongation step of 2 min at 60°C. Subsequent analysis and post‐processing were performed with the QuantStudio 3D AnalysisSuite Software.

Statistical analysis {#emmm201910941-sec-0020}
--------------------

Statistical analysis was carried out using Prism6 (GraphPad). *P* values were as follows: \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001, \*\*\*\**P* \< 0.0001. Scatterplots show mean and SEM. Box‐and‐whisker plots show median interquartile ranges plus minimum to maximum range. The number of animals is represented with *n*.
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